StreetInsider.com News Articles

Research Update

Fri, 07 Nov 2025 02:12:00 -0500

Scancell Holdings plc

Scancell holds oral presentation of positive Phase 2 data on Immunobody® iSCIB1+ in late-stage melanoma at SITC 2025

Data from SCOPE trial show a potential new benchmark in efficacy, durability, immune responses and safety

Progression-free survival (PFS) for iSCIB1+ in target population at 11 months is 78%, compared with historic 12 months PFS of 46% with doublet checkpoint therapy of ipilimumab and nivolumab

Development plans for iSCIB1+ accelerated including regulatory and partnering discussions, with randomised studies on path to registration expected to start in 2026

Research Update

Fri, 07 Nov 2025 02:12:00 -0500

Scancell Holdings plc

Scancell holds oral presentation of positive Phase 2 data on Immunobody® iSCIB1+ in late-stage melanoma at SITC 2025

Data from SCOPE trial show a potential new benchmark in efficacy, durability, immune responses and safety

Progression-free survival (PFS) for iSCIB1+ in target population at 11 months is 78%, compared with historic 12 months PFS of 46% with doublet checkpoint therapy of ipilimumab and nivolumab

Development plans for iSCIB1+ accelerated including regulatory and partnering discussions, with randomised studies on path to registration expected to start in 2026

Research Update

Fri, 07 Nov 2025 02:12:00 -0500

Scancell Holdings plc

Scancell holds oral presentation of positive Phase 2 data on Immunobody® iSCIB1+ in late-stage melanoma at SITC 2025

Data from SCOPE trial show a potential new benchmark in efficacy, durability, immune responses and safety

Progression-free survival (PFS) for iSCIB1+ in target population at 11 months is 78%, compared with historic 12 months PFS of 46% with doublet checkpoint therapy of ipilimumab and nivolumab

Development plans for iSCIB1+ accelerated including regulatory and partnering discussions, with randomised studies on path to registration expected to start in 2026

Research Update

Fri, 07 Nov 2025 02:12:00 -0500

Scancell Holdings plc

Scancell holds oral presentation of positive Phase 2 data on Immunobody® iSCIB1+ in late-stage melanoma at SITC 2025

Data from SCOPE trial show a potential new benchmark in efficacy, durability, immune responses and safety

Progression-free survival (PFS) for iSCIB1+ in target population at 11 months is 78%, compared with historic 12 months PFS of 46% with doublet checkpoint therapy of ipilimumab and nivolumab

Development plans for iSCIB1+ accelerated including regulatory and partnering discussions, with randomised studies on path to registration expected to start in 2026

Research Update

Fri, 07 Nov 2025 02:12:00 -0500

Scancell Holdings plc

Scancell holds oral presentation of positive Phase 2 data on Immunobody® iSCIB1+ in late-stage melanoma at SITC 2025

Data from SCOPE trial show a potential new benchmark in efficacy, durability, immune responses and safety

Progression-free survival (PFS) for iSCIB1+ in target population at 11 months is 78%, compared with historic 12 months PFS of 46% with doublet checkpoint therapy of ipilimumab and nivolumab

Development plans for iSCIB1+ accelerated including regulatory and partnering discussions, with randomised studies on path to registration expected to start in 2026

Research Update

Fri, 07 Nov 2025 02:12:00 -0500

Scancell Holdings plc

Scancell holds oral presentation of positive Phase 2 data on Immunobody® iSCIB1+ in late-stage melanoma at SITC 2025

Data from SCOPE trial show a potential new benchmark in efficacy, durability, immune responses and safety

Progression-free survival (PFS) for iSCIB1+ in target population at 11 months is 78%, compared with historic 12 months PFS of 46% with doublet checkpoint therapy of ipilimumab and nivolumab

Development plans for iSCIB1+ accelerated including regulatory and partnering discussions, with randomised studies on path to registration expected to start in 2026

Research Update

Fri, 07 Nov 2025 02:12:00 -0500

Scancell Holdings plc

Scancell holds oral presentation of positive Phase 2 data on Immunobody® iSCIB1+ in late-stage melanoma at SITC 2025

Data from SCOPE trial show a potential new benchmark in efficacy, durability, immune responses and safety

Progression-free survival (PFS) for iSCIB1+ in target population at 11 months is 78%, compared with historic 12 months PFS of 46% with doublet checkpoint therapy of ipilimumab and nivolumab

Development plans for iSCIB1+ accelerated including regulatory and partnering discussions, with randomised studies on path to registration expected to start in 2026

Research Update

Fri, 07 Nov 2025 02:12:00 -0500

Scancell Holdings plc

Scancell holds oral presentation of positive Phase 2 data on Immunobody® iSCIB1+ in late-stage melanoma at SITC 2025

Data from SCOPE trial show a potential new benchmark in efficacy, durability, immune responses and safety

Progression-free survival (PFS) for iSCIB1+ in target population at 11 months is 78%, compared with historic 12 months PFS of 46% with doublet checkpoint therapy of ipilimumab and nivolumab

Development plans for iSCIB1+ accelerated including regulatory and partnering discussions, with randomised studies on path to registration expected to start in 2026

Research Update

Fri, 07 Nov 2025 02:12:00 -0500

Scancell Holdings plc

Scancell holds oral presentation of positive Phase 2 data on Immunobody® iSCIB1+ in late-stage melanoma at SITC 2025

Data from SCOPE trial show a potential new benchmark in efficacy, durability, immune responses and safety

Progression-free survival (PFS) for iSCIB1+ in target population at 11 months is 78%, compared with historic 12 months PFS of 46% with doublet checkpoint therapy of ipilimumab and nivolumab

Development plans for iSCIB1+ accelerated including regulatory and partnering discussions, with randomised studies on path to registration expected to start in 2026

Research Update

Fri, 07 Nov 2025 02:12:00 -0500

Scancell Holdings plc

Scancell holds oral presentation of positive Phase 2 data on Immunobody® iSCIB1+ in late-stage melanoma at SITC 2025

Data from SCOPE trial show a potential new benchmark in efficacy, durability, immune responses and safety

Progression-free survival (PFS) for iSCIB1+ in target population at 11 months is 78%, compared with historic 12 months PFS of 46% with doublet checkpoint therapy of ipilimumab and nivolumab

Development plans for iSCIB1+ accelerated including regulatory and partnering discussions, with randomised studies on path to registration expected to start in 2026

Research Update

Fri, 07 Nov 2025 02:12:00 -0500

Scancell Holdings plc

Scancell holds oral presentation of positive Phase 2 data on Immunobody® iSCIB1+ in late-stage melanoma at SITC 2025

Data from SCOPE trial show a potential new benchmark in efficacy, durability, immune responses and safety

Progression-free survival (PFS) for iSCIB1+ in target population at 11 months is 78%, compared with historic 12 months PFS of 46% with doublet checkpoint therapy of ipilimumab and nivolumab

Development plans for iSCIB1+ accelerated including regulatory and partnering discussions, with randomised studies on path to registration expected to start in 2026

Research Update

Fri, 07 Nov 2025 02:12:00 -0500

Scancell Holdings plc

Scancell holds oral presentation of positive Phase 2 data on Immunobody® iSCIB1+ in late-stage melanoma at SITC 2025

Data from SCOPE trial show a potential new benchmark in efficacy, durability, immune responses and safety

Progression-free survival (PFS) for iSCIB1+ in target population at 11 months is 78%, compared with historic 12 months PFS of 46% with doublet checkpoint therapy of ipilimumab and nivolumab

Development plans for iSCIB1+ accelerated including regulatory and partnering discussions, with randomised studies on path to registration expected to start in 2026

Beroni Group Announces Appointment of Dr. John Chiplin to Board of Directors

Thu, 31 Mar 2022 08:25:00 -0500